Olmesartan Medoxomilo + Hidroclorotiazida Jubilant (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Jubilant, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure, often in combination with a diuretic, and is prescribed for adults.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Jubilant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is indicated for hypertension management within the renin‑angiotensin‑aldosterone system pathway. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with fluid retention: provides additional diuretic effect to improve blood pressure control. - High‑risk cardiovascular patients: assists in achieving target blood pressure when monotherapy is insufficient.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Cough - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate baseline creatinine and eGFR. - Electrolytes: check serum potassium and sodium levels. - Hepatic function: monitor liver enzymes in patients with liver disease. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: use with caution as they may reduce antihypertensive effect. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Olmesartan medoxil + hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Aliskiren (dual renin‑angiotensin system blockade increases risk of renal impairment). - Potassium‑sparing diuretics or supplements (risk of hyperkalemia). - Lithium (reduced clearance may lead to toxicity).

Moderate Interactions (Monitor Closely): - NSAIDs (may blunt antihypertensive response and affect renal function). - ACE inhibitors (combined use can cause additive hypotension and hyperkalemia). - Antidiabetic agents (diuretic effect may enhance hypoglycaemia).